(CercleFinance.com) – Invest Securities confirms its buy rating on Transgene shares, with a price target reduced from 5.7 to 5.4 euros.
The analyst firm reports that the company has presented a 2023 plan punctuated by several catalysts that should reinforce the first results announced in most of their clinical programs.
In particular, two clinical trials potentially opening the way to registration are planned in the short term in the therapeutic vaccine franchise.
‘2023 should be a year of consolidation, with 2024 shaping up to be the year of proof of concept’, says the analyst.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
